AKC CHF Receives 2022 Distinguished Research Partner Award from University of Minnesota

RALEIGH, NC (April 7, 2022) – The AKC Canine Health Foundation (CHF) has been awarded the 2022 Points of Pride Distinguished Research Partner Award from the University of Minnesota College of Veterinary Medicine.

The annual award recognizes CHF’s generous support for canine health research conducted at the University of Minnesota. Since 1995, CHF has awarded University of Minnesota investigators more than $5 million for 57 canine health research and educational grants, including one of the largest grants ever awarded by CHF to explore early cancer diagnosis. Outcomes from this research have improved our understanding of hemangiosarcoma, Addison’s Disease, epilepsy, and more.

Dr. Jennifer MacLeay, CHF Chief Scientific Officer, accepted the award today at a luncheon marking the College’s Points of Pride Research Day. This event honors University of Minnesota faculty, fellows, students, and alumni who distinguish themselves with the research they do, as well as partners and stakeholders who make much of this research possible.

“I am honored to accept this award on behalf of the CHF staff, board, and all of our valued donors. The University of Minnesota is one of the country’s premier veterinary health research institutions and has uniquely contributed to One Health,” says Dr. MacLeay. “The people of this university have been working at the leading edge of veterinary medicine for decades and we are so proud to know them as both researchers and dog lovers. We are proud to collaborate with them in making a difference in the health of current and future generations of dogs.”

CHF currently manages a portfolio of $13.3 million in 163 active research grants around the globe as they work to prevent, treat and cure canine disease. Learn more about these active studies at akcchf.org/research.

Short URL: https://caninechronicle.com/?p=229613

Posted by showresults on Apr 27 2022. Filed under Current Articles, Featured. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed.